


Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future

The NETest® – a Chromogranin A replacement and more?

ASCO 2017 – Let’s talk about NETs #ASCO17

The NETest is a non-invasive procedure that uses a blood sample to inform your doctor what the activity of your tumor is at the time your blood was drawn. Use of the NETest provides additional information about disease status that is complimentary to imaging and may decrease radiation exposure by decreasing the need for repetitive imaging. NETesting provides an assessment of treatment responses in neuroendocrine tumor patients in conjunction with standard clinical assessment. Interpretation of the test will facilitate identification of active disease and enable a determination of the efficacy of the current treatment modality. NETesting is as easy as having your blood drawn, and provides clinicians and patients with the information to better manage treatment.